France·Stock·Euronext ParisEssilorLuxottica Société anonyme (EL.PA)
Health Care · Medical Instruments & Supplies · Europe
Price in EUR, last 5 years
- Last price
- €175.65 (Oct 22, 2026)
- 1-year return
- -42.3%
- 3-year annual return
- +5.3%
- 5-year annual return
- +2.9%
- 1-year volatility
- 32.9%
- Max drawdown (5Y)
- -55.6%
- Market cap (approx.)
- US$90.1B
- History available
- since Jan 2, 2014
About EssilorLuxottica Société anonyme
EssilorLuxottica Société anonyme (EL.PA) is a stock from France that trades on Euronext Paris in EUR. It operates in the health care sector, Medical Instruments & Supplies industry. It's part of the Euro Stoxx 50.
Over the last year its price fell 42.3% in EUR, with annual volatility of 33%: a moderately volatile asset. Its worst drop over the last five years was 55.6% from a peak.
If your currency isn't the EUR, your real return will also depend on the exchange rate. In the optimizer you can choose your currency (USD, EUR, MXN, BRL, CLP, COP, PEN or ARS) and the calculation includes that currency risk.
How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.
Other health care assets in Europe
| Asset | 1 year | 1Y return | Volatility | Market cap | |
|---|---|---|---|---|---|
 Roche Holding AGROP.SW · Stock · Health Care | +43.5% | 24% | US$378.1B | ||
Novartis AGNOVN.SW · Stock · Health Care | +26.6% | 23% | US$298.0B | ||
 AstraZeneca PLCAZN.L · Stock · Health Care | +2.8% | 27% | US$266.9B | ||
GSK plcGSK.L · Stock · Health Care | +14.9% | 25% | US$101.6B | ||
SanofiSAN.PA · Stock · Health Care | -9.7% | 22% | US$99.9B | ||
 argenx SEARGX.BR · Stock · Health Care | +12.2% | 40% | US$56.1B | ||
Lonza Group AGLONN.SW · Stock · Health Care | +13.6% | 23% | US$53.4B | ||
Galderma Group AGGALD.SW · Stock · Health Care | +37.7% | 29% | US$52.9B |
Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.